ArticleFrontiers in molecular biosciences2026
Development of an application for colorectal cancer prediction using SDC2 and TFPI2 methylation: an opportunity for early and noninvasive diagnosis in Latin-America.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains a major public health challenge globally and within Latin-America, where expanding mortality rates are compounded by heterogeneous access to screening programs, healthcare infrastructure. While early detection is critical to improving survival rates, conventional fecal tests and colonoscopies face significant financial, logistical, and patient-adherence barriers in resource-limited settings. Epigenetic alterations, specifically promoter hypermethylation of CpG islands, occur early during the adenoma-carcinoma sequence and provide stable, highly sensitive targets for noninvasive molecular diagnostics. In this Perspective, we discuss the molecular rationale and complementary diagnostic value of combining two robustly validated epigenetic biomarkers, Syndecan-2 (SDC2), which modulates epithelial integrity and signaling, and Tissue Factor Pathway Inhibitor-2 (TFPI2), a critical serine protease inhibitor regulating extracellular matrix remodeling. Transcriptional silencing of these genes through aberrant hypermethylation reflects distinct yet commentary pathways of colorectal carcinogenesis, providing the molecular foundation for the implementation strategy proposed herein. To overcome technical barriers that currently limit the broader adoption of methylation-based screening, we present the integration of validated quantitative real-time PCR (qPCR) methylation assays with ColoGuardIA, an open-source, lightweight, Shiny-based digital application developed by our group as an implementation-oriented proof-of-concept platform. ColoGuardIA facilitates the standardized interpretation of qPCR-derived cycle threshold (Ct) values generated by previously validated methylation tests. By helping bridge the gap between molecular oncology and decentralized clinical implementation, this framework represents a scalable strategy to support the adoption of noninvasive methylation-based screening approaches and improve access to early colorectal cancer detection in Latin-America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.